跳至主要内容
临床试验/JPRN-UMIN000006943
JPRN-UMIN000006943招募中未知

Efficacy and safety of Entecavir/PEG-IFN-alpha sequential therapy for chronic active hepatitis B - Entecavir/PEG-IFN-alpha sequential therapy for chronic hepatitis B (B-SHOOT study)

Department of Hepatology, Osaka City University Graduate School of Medicine0 个研究点目标入组 50 人开始时间: 2015年3月31日最近更新:

试验速览

阶段
未知
状态
招募中
发起方
入组人数
50

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
ot applicable 至 ot applicable(—)
性别
All

入选标准

  • 未提供

排除标准

  • 1. presence of resistance to nucleoside analog (such as lamivudine and entecavir) 2. decompensated liver disease (total bilirubin >=2.0 mg/dL, prothrombin time <70 %, and albumin <3.6 g/dL) 3. other likely causes of chronic liver disease, such as autoimmune or alcoholic liver disease 4. severe complication (ex. impaired renal, cardiac or respiratory function) 5. women who are possibly pregnant, expectant mothers, and lactating mothers 6. history of interstitial pneumonitis 7. drug allegy to interferon 8. depression or other severe psychosomatic disorders 9. Unacceptable values of complete blood counts as follows: i) WBC counts=<3,000/microL ii) Neutrophil counts=<1,500/microL iii) Hemoglobin concentration=<12g/dL iv) Platelet counts=<90,000/micro

研究者

发起方
Department of Hepatology, Osaka City University Graduate School of Medicine

相似试验